Clinical Trial

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-24; most recent amendment 2026-05-20.
Trial Details
NCT Number NCT05800574
Lead Sponsor Fox Chase Cancer Center
Collaborators: Cardinal Health
Conditions Oropharynx Cancer
Enrollment 22 participants
Start Date 2023-03-14
Primary Completion 2026-09-23 (estimated)
Study Completion 2027-09-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-22